Gastroenterology

Gastroenterology

Volume 113, Issue 4, October 1997, Pages 1295-1305
Gastroenterology

Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas

https://doi.org/10.1053/gast.1997.v113.pm9322525Get rights and content

Abstract

BACKGROUND & AIMS: Chemotherapy of hepatocellular carcinomas is hampered by the insufficient accumulation of cytostatic drugs within the tumor cells. The aim of this study was to evaluate the feasibility of therapeutic strategies using antineoplastic agents coupled to bile acids.

METHODS: Expression of the Na(+)-taurocholate-cotransporting polypeptide (NTCP) was analyzed in six hepatocellular carcinomas and in nonmalignant liver tissue. Uptake of the cytostatic drug [3H]- chlorambucil-taurocholate (S2676) was measured in Xenopus laevis oocytes injected with total messenger RNA (mRNA) from the carcinomas or peritumor tissue or with complementary RNA encoding the NTCP or the organic anion-transporting polypeptide (OATP) of human liver.

RESULTS: Expression of hepatocellular carcinoma mRNA in oocytes resulted in mainly Na(+)-dependent uptake of chlorambucil-taurocholate. The level of NTCP mRNA in carcinomas amounted to 56% +/- 27% compared with peritumor tissue. Immunofluorescence studies confirmed the expression of NTCP on the surface of hepatocellular carcinoma cells. OATP expression, determined by immunoblotting, was similar in hepatocellular carcinomas and surrounding liver tissue (n = 3). NTCP mediated Na(+)- dependent uptake of chlorambucil-taurocholate (Michaelis constant, 11 mumol/L), whereas OATP mediated Na(+)-independent uptake.

CONCLUSIONS: Hepatocellular carcinomas express the Na(+)-dependent bile acid transporter NTCP. Because NTCP mediates high-affinity uptake of chlorambucil-taurocholate, targeting of cytostatic bile acids to hepatocellular carcinomas could become a feasible therapeutic strategy.

(Gastroenterology 1997 Oct;113(4):1295-305)

References (0)

Cited by (151)

  • Research progress in the application of bile acid-drug conjugates: A “trojan horse” strategy

    2021, Steroids
    Citation Excerpt :

    After coupling with BAs, the kidney elimination mode of chlorambucil is transformed to the hepatobiliary mode. Studies have shown that human HCCs express Na+-dependent basolateral BA transporters, which can mediate the uptake of the cytostatic agent chlorambucil coupled to taurocholate [41]. In 1997, Criado et al. [85,88] used this strategy to target platinum-metal anticarcinogens in the hepatobiliary system, which solved the application limitation of nephrotoxicity, myelotoxicity, neurotoxicity, nausea, and vomiting caused by its lack of selectivity and susceptibility to drug resistance.

  • Bile acid transporter as a bioinspired method for oral therapeutics delivery system

    2021, Bioinspired and Biomimetic Materials for Drug Delivery
  • Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy

    2019, Pharmacology and Therapeutics
    Citation Excerpt :

    Bile acids-chlorambucil conjugates were also designed to change the normal route of elimination of chlorambucil (kidney excretion) to a hepatobiliary one. A chlorambucil-taurocholate conjugate was shown to maintain the pharmacological activity of the parent DNA alkylating drug (Kullak-Ublick et al., 1997). Very recently, bile acids were conjugated to dihydroartemisinin (DHA) to afford a series of cytotoxic hybrid molecules (Marchesi et al., 2019).

View all citing articles on Scopus
View full text